Patients who received oral paclitaxel with encequidar had lower rates of neuropathy, but higher rates of neutropenia, anemia, and gastrointestinal adverse events.
Image-guided core-needle biopsy did not improve the predictive value of trimodality imaging after neoadjuvant therapy for patients with operable breast cancer.
Estrogen alone and estrogen plus progestin appeared to have “opposite effects” on risk of breast cancer and death among postmenopausal women.
A multicenter pooled analysis found that residual cancer burden index after neoadjuvant therapy was prognostic in the long-term across 4 breast cancer subtypes.
The quantitative burden of ctDNA was also associated with significantly worse distant disease-free survival.
Many breast cancer drugs approved in the United States may lack substantial clinical benefit, particularly in the palliative setting.
Exploratory subgroup analyses suggest patients with triple-negative breast cancer or PDL1-positive tumors may benefit from maintenance durvalumab.
A fixed-dose combination of subcutaneous pertuzumab and trastuzumab was found to be noninferior for patients with HER2-positive breast cancer.
Compared to historical controls, adjuvant paclitaxel and trastuzumab seems to provide the same benefit for patients with low-risk, HER2-positive early breast cancer.
Researchers warn that pathologists may be assigning the wrong immune cell score with PD-L1 assays to patients, leading to inappropriate treatment recommendations.
